Biomarkers in acute coronary syndrome

Biomarker Insights

Volumn 2008, Issue 3, 2008, Pages 453-468

  Loria, Valentina ^a   Leo, Milena ^a   Biasillo, Gina ^a   Dato, Ilaria ^a   Biasucci, Luigi M ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE; CREATINE KINASE MB; FATTY ACID; FATTY ACID BINDING PROTEIN; FREE FATTY ACID UNBOUND TO ALBUMIN; GELATINASE B; MYELOPEROXIDASE; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PROTEIN; PREGNANCY ASSOCIATED PROTEIN A; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANGINA PECTORIS; ATHEROSCLEROTIC PLAQUE; CLINICAL ASSESSMENT; CLINICAL TRIAL; DIAGNOSTIC VALUE; ELECTROCARDIOGRAM; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STANDARDIZATION; THORAX PAIN;

EID: 56349135038     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: 10.4137/bmi.s588     Document Type: Review

References (129)

1. Adams, J.E., Kleinfeld, A., Roe, M. et al. 2002. Measurement of unbound free fatty acid allows the identifi cation of patients with acute coronary syndrome. Circulation, 106 8(Suppl 1):532.
2. American Heart Association: 2004. Heart and Stroke Statistical Update.
3. Anderson, J.L., Adams, C.D., Antman, E.M. et al. 2007. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non - ST-Elevation Myocardial Infarction. J. Am. Coll. Cardiol., 50:1-157.
4. Apple, F.S. 1999. Clinical and analytical standardization issues confronting cardiac troponin. I. Clin. Chem., 45(2):18-20.
5. Apple, F.S., Pearce, L.A. and Chung, A. 2007. Multiple biomarker use for detection of adverse events in patients presenting with symptoms suggestive of acute coronary syndrome. Clin. Chem., 53(5):874-81.
6. Apple, F.S., Wu, A.H., Mair, J. et al. 2005. Future biomarkers for detection of ischemia and risk stratifi cation in acute coronary syndrome. Clin. Chem., 51(5):810-24.
7. Autiero, M., Luttun, A., Tjwa, M. et al. 2003. "Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel target for stimulation of ischemic tissue revascularization and inhibition of angiogenic and infl ammatory disorders. J. Thromb. Haemost, 1:1356-70. Review.
8. Baldus, S., Heeschen, C., Meinertz, T. et al. 2003. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation, 108:1440-5.
9. Bayes-Genis, A., Con over, C.A., Overgaard, M.T. et al. 2001. Pregnancy-associated PAPP-A as a marker of acute coronary syndromes. N. Engl. J. Med., 345:1022-9.
10. Bertrand, M.E., Simoons, M.I., Fox, K.A. et al. 2002. Management of acute coronary syndromes in patients without persistent ST-segment elevation. Eur. Heart J., 23:1809-40.
11. Bhagavan, N.V., Lai, E.M., Rios, P.A. et al. 2003. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin. Chem., 49(4):581-5.
12. Biasucci, L.M., Abbate, A. and Liuzzo, G. 2003. Prognostic role of high-sensitivity C-reactive protein levels in acute coronary sindrome. In: Wu AH, (ed). Cardiac Markers 2nd. Humana, Totowa, NJ., (ed):291-303.
13. Biasucci, L.M., D'Onofrio, G., Liuzzo, G. et al. 1996. Intracellular neutrophil myeloperoxidase is reduced in unstable angina and acute myocardial infarction but its reduction but its reduction is not related to ischemia". J. Am. Coll. Cardiol., 27:611-6.
14. Biasucci, L.M., Liuzzo, G., Grillo, R.L. et al. 1999. Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability. Circulation, 99:855-60.
15. Biasucci, L.M., Niccoli, G., Biscione, C., Fusco, B. et al. 2000. Independent prognostic value of C-reactive protein levels for in-hospital death and myocardial infarction in unstable angina. Circulation, 102(Suppl II):140.
16. Blankenberg, S., Rupprecht, H.J., Poirier, O. et al. 2003. Plasma concentrations and genetic and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation, 107:1579-85.
17. Brennan, M.L., Penn, M.S., Van Lente, F. et al. 2003. Prognostic value of Myeloperoxidase in patients with chest pain. N. Engl. J. Med., 349:1595-604.
18. Cavusoglu, E., Ruwende, C., Eng, C. et al. 2007 May 15. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am. J. Card., 99(10):1364-8.
19. Christenson, R.H. and Azzazy, HME. 1998. Biochemical markers of acute coronary syndromes. Clin. Chem., 44:1855-64. Review.
20. Christenson, R.H., Hong, D.S., Sanhai, W.R. et al. 2001. Characteristics of an Albumin Cobalt Binding Test for assessment of Acute Coronary Syndrome patients: a multicenter study. Clinical Chemistry, 47:464-70.
21. Clerico, A., Iervasi, G. and Mariani, G. 1999. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm. Metab. Res., 31(9):487-98.
22. Collinson, P.O., Gerhardt, W., Katus, H.A. et al. 1996. Multicentre evaluation of an immunological test for the detection of Troponin T in whole blood samples. Clin. Chem. Clin. Biochem., 34:591-608.
23. Cowie, M.R., Jourdain, P., Maisel, A. et al. 2003. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur. Heart J., 24:1710-18.
24. Dabek, J., Kulach, A. and Gasior, Z. 2007 Oct. The role of matrix metalloproteinases in acute coronary syndromes. Eur. J. Int. Med., 18(6):463-6.
25. Davies, M. 1995. "Acute coronary thrombosis: the role of plaque disruption and its initiation and prevention." Eur. Heart J., 16:3-7. Review.
26. Davies, M. 1997. The composition of coronary artery plaque. N. Engl. J. Med., 336:1312-3.
27. Davies, M.J., Richardson, P.J., Woolf, N. et al. 1993. Risk of thrombosis in human atherosclerotic plaques:role of extracellular lipid, macrophage, and smooth cell content. Br. Heart J., 69(5):377-81.
28. de Groot, M.J., Wodzig, K.W., Simoons, M.L. et al. 1999. Measurement of myocardial infarct size from plasma fatty acid-binding protein or myoglobin, using individually estimated clearance rates. Cardiovasc. Res., 44(2):315-24.
29. de Lemos, J.A. and Morrow, D.A. 2002. Brain natriuretic peptide measurement in acute coronary syndromes. Ready for clinical application? Circulation, 106:2868-70.
30. deFilippi, C.R., Seliger, S.L., Maynard, S. and Christenson, R.H. 2007 Aug. Impact of renal disease on natriuretic peptide testing for diagnosing decompensated heart failure and predicting mortality. Clin. Chem., 53(8):1511-9. Epub 2007 Jun 22.
31. Dollery, C.M. and Libby, P. 2006 Feb 15. Atherosclerosis and protease activation. Cardiovasc. Res., 69(3):625-35.
32. D'Souza, S.P. and Baxter, G.F. 2003. B-type natriuretic peptide: a good omen in myocardial ischemia? Heart, 89(7):707-9.
33. Fialova, L., Kalousova, M., Soukupova, J. et al. 2004. Relationship of pregnancy associated plasma protein A (PAPP-A to renal function and dialysis modalities. Kidney Blood Press Res., 27:88-95.
34. Fiotti, N., Altamura, N., Orlando, C. et al. 2007 Aug 14. Metalloproteinases-2, -9 and TIMP-1 expression in stable and unstable coronary plaques undergoing PCI. Int. J. Cardiol.
35. Freda, B.J., Tang, W.H., van Lente, F. et al. 2002. Cardiac troponins in renal insufficiency. Review and clinical implications. J. Am. Coll Card, 40:2065-71.
36. Galis, Z., Muszynski, M., Sukhova, G.K. et al. 1994. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. J. Clin. Invest., 75:181-9.
37. Galis, Z., Sukhova, G., Lark, M. et al. 1994. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 94:2493-503.
38. Galvani, M., Ottani, F., Ferrini, D. et al. 1997. Prognostic infl uence of elevated values of cardiac Troponin I in patients with unstable angina. Circulation, 95(8):2053-9.
39. Galvani, M., Ottani, F., Oltrona, L. et al. 2004 Jul 13. N.-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation, 110(2):128-34.
40. Gibler, W.B., Lewis, L.M., Erb, R.E. et al. 1990. Early detection of acute myocardial infarction in patients presenting with chest pain and nondiagnostic electrocardiograms: serial CK-MB. sampling in the emergency department. Ann. Emerg. Med., 19:1359-66.
41. Gillis, T.E., Marshall, C.R. and Tibbis, G.F. 2007. Functional and evolutionary relationships of Troponin C. Physiol. Genomic., 32(1):16-27.
42. Haft, J.I. and Saadeh, S.A. 1997. Cardiac troponins in acute coronary syndromes. N. Engl. J. Med., 336(17):1257.
43. Hall, C. 2005. NT-proBNP: the mechanism behind the marker. J. Card Fail, 11(Suppl 5):581-83.
44. Hamm, C.W., Goldman, B.U., Heeschen, C. et al. 1997. Emergency room triage of patients with acute chest pain by means of rapid testing for cardiac troponin T or troponin I. N. Engl. J. Med., 337(23):1648-53.
45. Hamm, C.W., Heeschen, C., Goldman, B. et al. 1999. For the CAPTURE investigations. Benefit of the abciximab with refractory unstable angina in relation to serum troponin T levels. N. Engl. J. Med., 340:1623-9.
46. Heeschen, C., Dimmeler, S., Fichtlscherer, S. et al. 2004. Prognostic value of placental growth factor in patients with acute chest pain." JAMA, 291:435-41.
47. Heeschen, C., Dimmeler, S., Hamm, C.W. et al. 2003. CAPTURE Study Investigators. Soluble CD40L in acute coronary syndromes. N. Engl. J. Med., 348:1104-11.
48. Heeschen, C., Fichtlscherer, S. and Hamm, C.W. 2003. Pregnancy associated plasma protein A (PAPP-A) plasma level indipendently predicte outcome in patients with acute coronary sindrome. Circulation, 108(suppl IV):470.
49. Heeschen, C., Hamm, C.W., Bruemmer, J. et al. 2000. For the CAPTURE Investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J. Am. Coll. Cardiol., 35:1535-42.
50. Heeschen, C., Hamm, C.W., Goldman, B. et al. 1999. Troponin concentrations for stratification of patients with acute coronary syndromes in relation o therapeutic effi cacy of tirofi ban. PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet, 354:1757-62.
51. Heeschen, C., Hamm, C.W., Mitrovic, V. et al. 2004. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-Terminal Pro-B-Type Natriuretic Peptide Levels for Dynamic Risk Stratification of Patients With Acute Coronary Syndromes. Circulation, 110(20):3206-12.
52. Heymas, S., Luttun, A., Nuyens, D. et al. 1999. Inhibition of plasminogenon activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat. Med., 5:1135-42.
53. Holvoet, P. 1998. Oxidative modification of low-density lipoproteins in atherothrombosis. Acta. Cardiol., 53(5):253-60.
54. Hunt, P.J., Yandle, T.G., Nicholls, M.G. et al. 1995 Sep 25. The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem. Biophys. Res. Commun., 214(3):1175-83.
55. Inokubo, Y., Hanada, H., Ishikaza, H. et al. 2001. Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloprotease-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am. Heart J., 141:211-7.
56. Ishii, J., Nakamura, Y., Naruse, H. et al. 2003. Heart-type fatty acid-binding protein is a useful marker for the diagnosis of acute myocardial infarction and risk stratifi cation of cardiac mortality and cardiac events in patients with early hours of acute coronary syndrome. Heart, 89:1303-7.
57. Jaffe, A.S. 2001. Elevation in cardiac troponin measurements: false-positives: the real truth. Cardiovasc. Toxicol., 1:87-92.
58. Jaffe, A.S., Ravkilde, J., Roberts, R. et al. 2000. It's time for a change to a troponin standard. Circulation, 102:1216-20.
59. James, S.K., Armstrong, P., Barnathan, E. et al. 2003. Troponin T and C-reactive protein have a different relation to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy. J. Am. Coll. Cardiol., 41:916-24.
60. Jernberg, T., James, S., Lindahl, B. et al. 2004 Mar 15. NT-proBNP in unstable coronary artery disease: experiences from the FAST, GUSTO IV and FRISC II trials. Eur. J. Heart Fail., 6(3):319-25.
61. Jouven, X., Charles, M.A., Desnos, M. et al. 2001. Circulating nonesterified fatty acid lavel as predective risk factor for sudden death in the population. Circulation, 104:756-61.
62. Kai, H., Ikeda, H., Yasukawa, H. et al. 1998. Peripheral blood levels of matrix metalloprotease-2 and -9 are elevated in patients with acute coronary syndromes. J. Am. Coll. Cardiol., 32:368-72.
63. Kavsak, P.A., Newman, A.M., Lustig, V. et al. 2007 Feb. Long-term health outcomes associated with detectable troponin I concentrations. Clin. Chem., 53(2):220-7.
64. Kay, J.D., Trichon, B.H., Kisslo, M. et al. 2003. Serum brain natriuretic peptide levels cannot differentiate pulmonary disease from left-heart failure if the right ventricle is dilated. Circulation, 108:IV-397.
65. Kemperman, H., Van den Berg, M., Kirkels, H. et al. 2004. B-type natriuretic peptide (BNP) and N-Terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clinical Chemistry, 50:1670-2.
66. Kikuta, K., Yasue, H., Yoshimura, M. et al. 1996. Increased plasma levels of B-type natriuretic peptide in patients with unstable angina". Am. Heart J., 132(1Pt 1):101-7.
67. Klebanoff, S.J. 1999. Myeloperoxidase. Proc. Assoc. Am. Physicians, 111(5):383-9.
68. Kleine, A.H., Glatz, J.F., Van Nieuwenhoven, F.A. et al. 1992. Release of heart free fatty acid-binding protein into plasma after acute myocardial infarction in man. Mol. Cell Biochem., 116(1-2):155-62.
69. Kleinfeld, A.M., Kleinfeld, K.J. and Adams, J.E. 2002. Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute coronary syndrome in patient samples from the TIMI II trial". J. Am. Coll. Cardiol., 39:312A.
70. Lawrence, J.B., Oxvig, C., Overgaard, M.T. et al. 1999. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein A. Proc. Natl. Acad. Sci. U.S.A., 96:3149-53.
71. Lee, T.H., Rouan, G.W., Weisberg, M.C. et al. 1987. Clinical characteristics and natural history of patients with acute myocardial infarction sent home from the emergency room. Am. J. Cardiol., 60(4):219-24.
72. Lindahl, B., Lindbäck, J., Jernberg, T. et al. 2005 Feb 15. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J. Am. Coll. Cardiol., 45(4):533-41.
73. Lindahl, B., Toss, H., Siegbahn, A. et al. 2000. Markers of myocardial damage and infl ammation in relation to long-term mortality in unstable coronary artery desease. N. Engl. J. Med., 343:1139-47.
74. Lindahl, B., Venge, P., Wallentin, L. and Troponin, T. 1997. Identifies patients with unstable coronary artery diseasewho benefit from long-term anti-thrombotic protection. FRISC study group. JACC, 29(1):43-8.
75. Liuzzo, G., Biasucci, L.M., Gallimore, J.R. et al. 1994. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N. Engl. J. Med., 331:417-24.
76. Lund, J., Qin, Q.P., IIva, T. et al. 2003. Circulating pregnancy-associated plasma protein A predicts outcome in patients with acute coronary syndromes. Circulation, 108:1924-6.
77. Luttun, A., Tjwa, M., Moons, L. et al. 2002. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat. Med., 8(8):831-40.
78. Maglione, D., Guerriero, V., Viglietto, G. et al. 1991. Isolation of human placenta cDNA coding for a protein related to the vascular permeabilità factor". Proc. Natl. Acad. Sci. U.S.A., 88:9267-71.
79. Mocatta, T.J., Pilbrow, A.P., Cameron, V.A. et al. 2007 May 22. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J. Am. Coll. Cardiol., 49(20):2001-2.
80. Morita, E., Yasue, H., Yoshimura, M. et al. 1993. "Increased plasma levels of brain natriuretic peptide in patients with acute coronary infarction". Circulation, 88(1):82-91.
81. Morrow, D.A. and Braunwald, E. 2003. Future of biomarkers in acute coronary syndromes. Moving toward a multimarker strategy. Circulation, 108:250-2.
82. Morrow, D.A., Rifai, N., Antman, E.M. et al. 1998. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary symdromes: a TIMI 11A substudy. J. Am. Coll. Cardiol., 31:1460-5.
83. Mueller, C., Buettner, H.J., Hodgson, J.M. et al. 2002. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation, 105:1412-5.
84. NACB Writing Group, Wu, A.H., Jaffe, A.S., Apple, F.S., Jesse, R.L., Francis GL, Morrow, D.A., Newby, L.K., Ravkilde, J., Tang, W.H., Christenson RH; NACB Committee, Cannon CP, Storrow AB. 2007. National Academy of Clinical Biochemistry laboratory medicine practice guidelines: use of cardiac troponin and B-type natriuretic peptide or N-terminal proB-type natriuretic peptide for etiologies other than acute coronary syndromes and heart failure. Clin Chem. Dec; 53(12):2086-96. Epub 2007 Oct.
85. Nagahara, D., Nakata, T., Hashimoto, A. et al. 2006. Early positive biomarker in relation to myocardial necrosis and impaired fatty acid metabolism in patients presenting with acute chest pain at an emergency room. Circ. J., 70(4):419-25.
86. Nakata, T., Hashimoto, A., Hase, M. et al. 2003. Human heart-type fatty acid-binding protein as an early diagnostic and prognostic marker in acute coronary syndrome. Cardiology, 99(2):96-104.
87. Ockner, R.K., Manning, J.A., Poppenhausen, R.B. et al. 1972. A binding protein for fatty acids in cytosol of intestinal mucosa, liver, myocardium, and other tissues. Science, 177:56-8.
88. O'Donoghue, M., de Lemos, J.A., Morrow, D.A. et al. 8 August 2006. Prognostic Utility of Heart-Type Fatty Acid Binding Protein in Patients With Acute Coronary Syndromes. Circulation, 114(6):550-7.
89. Ohman, E.M., Armstrong, P.W., Christenson, R.H. et al. 1996. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. N. Engl. Med. J., 335:1333-41.
90. Okamoto, F., Sohmiya, K., Ohkaru, Y. et al. 2000. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatinine chinase isoenzyme MB." Clin. Chem. Lab. Med., 38(3):231-8.
91. Olatidoye, Wu, A.H., Feng, Y.J. et al. 1998. Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am. J. Cardiol., 81:1405-10.
92. Oxvig, C., Sand, O., Kristensen, T. et al. 1993. Circulating human pregnancy-associated plasma protein A is disulfi de-bridged to the proform of eosinophiil major basic protein. J. Biol. Chem., 268:12243.
93. Panteghini, M., Cuccia, C., Pagani, F. et al. 2002. Coronary angiographic findings in patients with clinical unstable angina according to cardiac Troponin I and T concentrations in serum. Arch. Pathol. Lab. Med., 126:448-51.
94. Panteghini, M., Pagani, F. and Bonetti, G. 1999. The sensitivity of cardiac markers: an evidence-based approach. Clin. Chem. Lab. Med., 37:1097-106.
95. Peacock, F., Morris, D.L., Anwaruddin, S. et al. 2006. Meta-analysis of ischemia-modified albumin to rule out acute coronary syndromes in the emergency department. American Heart Journal, 152:253-62.
96. Pearson, J.R. and Carrea, F. 1990. Evaluation of the clinical usefulness of a chemiluminometric method for measuring creatine kinase MB. Clin. Chem., 36:1809.
97. Pearson, T.A., Mensah, G.A., Alexander, R.W. et al. 2003. Markers of infl ammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation, 107:499-511.
98. Pilz, S., Scharnagl, H., Tiran, B. et al. 2006 Jul. Related Articles, Free fatty acids are independently associated with all-cause and cardiovascular mortality in subjects with coronary artery disease. J. Clin. Endocrinol. Metab., 91(7):2542-7.
99. Pirro, M., Mauriège, P., Tchernof, A. et al. 2002. Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis, 160(2):377-84.
100. Pollack, C.V. and Peacock, F.W. 2003. Summers R.W. et al. Ischemia-modified albumin (IMA) is useful in risk stratification of emergency department chest pain patients. Acad. Emerg Med., 10:555-6.
101. Pope, J.H., Ruthazer, R., Beshansky, J.R. et al. 1998. Clinical features of Emergency Department patients presenting with symptoms suggestive of acute cardiac ischemia: a multicenter study. Journal of Thrombosis and Trombolysis, 6:63-74.
102. Quin, Q.P., Laitinen, P., Majamaa-Voltti, K. et al. 2002. Release pattern of pregnancy associated plasma protein A (PAPP-A) in patients with acute coronary syndromes. Scand Cardiovasc. J., 36:358-61.
103. REACTT Investigators Study Group. 1997. Evaluation of a bedside whole-blood rapid Troponin T assay in the emergency department. Academ. Emerg. Med., 4:1018-24.
104. Rebuzzi, A.G., Quaranta, G., Liuzzo, G. et al. 1998. Incremental prognostic value of serum levels of troponin T and C-reactive prognosis on admission in patients with unstable angina pectoris. Am. J. Cardiol, 82:715-9.
105. Ridker, P.M., Cannon, C.P., Morrow, D. et al. 2005. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy - Thrombolysis in Myocardial Infarction 22 (PROVE IT - TIMI 22) Investigators. New Engl. J. of Med., 352:20-8.
106. Ridker, P.M., Rifai, N., Rose, L. et al. 2002. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of fi rst cardiovascular events. N. Engl. J. Med., 347(20):1557-65.
107. Sabatine, M.S., Morrow, D.A., de Lemos, J.A. et al. 2002. Multimarker Approach to Risk Stratification in Non-ST Elevation Acute Coronary Syndromes: Simultaneous Assessment of Troponin I, C-Reactive Protein, and B-Type Natriuretic Peptide. Circulation, 105(15):1760-3.
108. Scirica, B.M., Morrow, D.A., Cannon, C.P. et al. 2007. Thrombolysis in Myocardial Infarction (TIMI) study Group. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin. Chem., 53(10):1800-7.
109. Seino, Y., Tomita, Y., Takano, T. et al. 2004. Tokyo Rapid-Test Offi ce Cardiologists (Tokyo-ROC) Study. Offi ce cardiologists cooperative study on whole blood rapid panel tests in patients with suspicious acute myocardial infarction: comparison between heart-type fatty acid-binding protein and troponin T tests. Circ. J., 68(2):144-8.
110. Sinha, M.K., Roy, D., Gaze, D.C. et al. 2004. Role of ischemia-modified albumin, a new biochemical marker of myocardial ischemia, in the early diagnosis of acute coronary syndrome. Emerg. Med. J., 21(1):29-34.
111. Struthers, A.D. 1999. How to use natriuretic peptide levels for diagnosis and prognosis. Eur. Heart J., 20:1374-5.
112. Suzuki, M., Hori, S., Noma, S. et al. 2005. Prognostic value of a qualitative test for heart-type fatty acid-binding protein in patients with acute coronary syndrome. Int. Heart J., 46(4):601-6.
113. Takahiko, N., Ueda, M., Haze, K. et al. 2002. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation, 106:2894-900.
114. Tambara, K., Fujita, M., Miyamoto, S. et al. 2004. Pericardial fluid level of heart-type cytoplasmatic fatty acid-binding protein (H-FABP) is an indicator of severe myocardial ischemia. Int. J. Cardiol., 93(1-2):281-4.
115. Tateishi, J., Masutani, M., Ohyanagi, M. et al. 2000. Transient increase in plasma brain (B-type) natriuretic peptide after percutaneous transluminal coronary angioplasty. Clin. Cardiol., 23(10):776-80.
116. Thygesen, K., Joseph, S., Alpert, Harvey, D. and White, October 2007. Universal definition of myocardial infarction. Circulation, 116:2634-53.
117. Tjwa, M., Luttun, A., Autiero, M. et al. 2003. VEGF and PIGF: two pleiotropic growth factors with distinct roles in development and homeostasis. Cell. Tissue Res., 314:5-14. Review.
118. Tsuji, R., Tanaka, T., Sohmiya, K. et al. 1993. Human heart-type cytoplasmatic fatty acid-binding protein in serum and urine during hyperacute myocardial infarction. Int. J. Cardiol., 41(3):209-17.
119. Van Nieuwenhoven, F.A., Kleine, A.H., Wodzig, W.H. et al. 1995. Discrimination between myocardial and skeletal muscle injury by assessment of the plasma ratio of myoglobin over fatty acid-binding protein. Circulation, 92(10):2848-54.
120. Varo, N., de Lemos, J.A., Libby, P. et al. 2003. Soluble CD40L: risk prediction after acute coronary syndromes. Circulation, 108(9):1049-52.
121. Visse, R. and Nagase, H. 2003. Matrix metalloproteinases and tissue inhibitors of metalloproteinases; structure, function and biochemistry. Circ. Res., 92:827-39.
122. Volanakis, J.E. 2001. Human C-reactive protein: expression, structure, and function. Molecular Immunology, 38(2-3):189-97.
123. Wald, N.J., Gorge, L., Smith, D. et al. 1996. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy for the International Prenatal Screening researche group. Br. J. Obstet. Gynaecol., 103:407-12.
124. Wang, T.J., Larson, M.G., Levy, D. et al. 2004. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N. Engl. J. Med., 350(7):655-63.
125. Weber, M. and Hamm, C. 2006 Jun. Role of B.-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart, 92(6):843-9.
126. White, H.D. and French, J.K. 2003. Use of brain natriuretic peptide levels for risk assessment in non-ST elevation acute coronary syndromes. J. Am. Coll. Cardiol, 42(11):1917-20.
127. Worster, A., Devereaux, P.J., Heels-Ansdell, D. et al. 2005. Capability of ischemia-modified albumin to predict serious cardiac outcomes in the short term among patients with potential acute coronary syndrome. Canadian Medicine Association Journal, 172(13):1685-90.
128. Wu, A.H. 2003. The ischemia-modified albumin biomarker for myocardial ischemia. MLO Med. Lab. Obs., 6:36-40.
129. Zhang, R., Brennan, M.L., Fu, X. et al. 2001. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA, 286:2136-42.